Uzm. Dr. Burcu Kolukısa

Multidimensional Assessment of Patient-Reported-Outcomes in a Multicenter Cohort of Inborn Errors of Immunity

Journal of Clinical Immunology, 2026

DOI 10.1007/s10875-025-01972-1 PMID 41493669 Frei zugänglicher VolltextQuelle: OpenAlex

Early-Life Wheezing and Atopic Burden Are Associated with Treatment-Defined Asthma Severity and Control in School-Age Children: A Two-Center Cross-Sectional Study

Journal of Clinical Medicine, 2026

DOI 10.3390/jcm15166459 PMID 42652863 Frei zugänglicher VolltextQuelle: ORCID

Algorithms in Allergy: Elevated IgE in Pediatric Patients

Allergy, 2026

DOI 10.1111/all.70376 PMID 42083109 Quelle: ORCID

A plain language summary of a study looking at the effects of pozelimab in children with CHAPLE disease

Future Rare Diseases, 2025

DOI 10.1080/23995270.2025.2498826 Frei zugänglicher VolltextQuelle: OpenAlex

Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study

The Lancet, 2024

DOI 10.1016/s0140-6736(23)02358-9 PMID 38278170 26 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Evaluation of Clinical and Immunological Alterations Associated with ICF Syndrome

Journal of Clinical Immunology, 2024

DOI 10.1007/s10875-023-01620-6 PMID 38129713 10 Zitationen (Europe PMC) Quelle: ORCID

A Phase 2/3 Study Evaluating the Efficacy and Safety of Pozelimab in Patients with CD55 Deficiency with Hyperactivation of Complement, Angiopathic Thrombosis, and Protein-Losing Enteropathy (CHAPLE Disease)

SSRN, 2023

DOI 10.2139/ssrn.4485593 Quelle: ORCID

Human carmil2 deficiency underlies a broader immunological and clinical phenotype than cd28 deficiency

Journal of Experimental Medicine, 2023

DOI 10.1084/jem.20220275 PMID 36515678 34 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

25 A phase 2/3 study evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE disease)

Immunobiology, 2023

DOI 10.1016/j.imbio.2023.152482 3 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

Expanding the Clinical and Immunological Phenotypes and Natural History of MALT1 Deficiency

Journal of Clinical Immunology, 2022

DOI 10.1007/s10875-021-01191-4 PMID 35079916 35 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

Adverse COVID‐19 outcomes in immune deficiencies: Inequality exists between subclasses

Allergy, 2022

DOI 10.1111/all.15025 PMID 34314546 32 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Evolution and long-term outcomes of combined immunodeficiency due to CARMIL2 deficiency

Allergy: European Journal of Allergy and Clinical Immunology, 2022

DOI 10.1111/all.15010 PMID 34287962 43 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Clinical, immunological, molecular and therapeutic findings in monogenic immune dysregulation diseases: Middle East and North Africa registry

Clinical Immunology, 2022

DOI 10.1016/j.clim.2022.109131 PMID 36179983 19 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

Immune dysfunction in inborn errors of immunity causing malignancies

Expert Review of Clinical Immunology, 2021

DOI 10.1080/1744666x.2021.1925542 PMID 33945379 6 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Primary Immune Regulatory Disorders and Targeted Therapies

Turkish Journal of Hematology, 2021

DOI 10.4274/tjh.galenos.2021.2020.0724 PMID 33442967 9 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Adverse covid outcomes in youngsters with immune deficiencies; inequality exists between subclasses

Dspace Repository (Marmara Üniversitesi), 2021

Quelle: OpenAlex

Protein-Losing Enteropathies: an Update on Etiologic Classification

2020

Quelle: OpenAlex